Target Name: USP41
NCBI ID: G373856
Review Report on USP41 Target / Biomarker Content of Review Report on USP41 Target / Biomarker
USP41
Other Name(s): Ubiquitin specific peptidase 41 | Ubiquitin thioesterase 41 | ubiquitin specific peptidase 41 | Ubiquitin-specific-processing protease 41 | Deubiquitinating enzyme 41 | UBP41_HUMAN | Ubiquitin thiolesterase 41 | Putative ubiquitin carboxyl-terminal hydrolase 41 | Ubiquitin specific protease 41 | Ubiquitin specific proteinase 41

USP41: A promising drug target and biomarker for the treatment of cancer

USP41 (Ubiquitin specific peptidase 41) is a protein that plays a crucial role in the regulation of protein degradation in the body. It is a 21-kDa enzyme that is expressed in various tissues and cells, including the brain, muscle, heart, and organs. USP41 has been identified as a potential drug target and biomarker for the treatment of cancer due to its unique mechanism of action and its expression in cancer cells.

The mechanism of action of USP41

USP41 is an enzyme that uses specific Ubiquitin proteins to cleave and remove them from target proteins. This process is a crucial step in the regulation of protein degradation and is essential for the proper functioning of cells. USP41 recognizes and binds to specific Ubiquitin proteins, which are involved in various cellular processes such as cell signaling, DNA replication, and stress response.

Once bound, USP41 uses its catalytic activity to cleave the Ubiquitin protein from its target protein. This process not only removes the Ubiquitin protein but also regulates the levels of Ubiquitin in the cell. This allows the cell to maintain a balance of protein levels and to remove damaged or unnecessary proteins.

USP41 has been shown to play a crucial role in the regulation of various cellular processes, including cell signaling, DNA replication, and stress response. It has been shown to be involved in the development and progression of various types of cancer, including colon cancer, breast cancer, and lung cancer.

The potential clinical applications of USP41

The potential clinical applications of USP41 are vast and include the treatment of various types of cancer. USP41 has been shown to be involved in the regulation of cancer cell growth, survival, and angiogenesis, which are critical processes for the development and progression of cancer.

One of the potential benefits of USP41 as a drug target is its ability to selectively target cancer cells while minimizing the impact on healthy cells. This is achieved through its expression in cancer cells, which allows it to survive and function in the presence of cancer-associated molecules.

Another potential benefit of USP41 is its ability to act as a biomarker for the diagnosis and monitoring of cancer. USP41 has been shown to be expressed in various types of cancer and has been used as a biomarker for the diagnosis of cancer. This allows for the early detection and monitoring of cancer, which has a significant impact on treatment outcomes.

The potential clinical applications of USP41 are vast and include the treatment of various types of cancer, as well as the use as a biomarker for cancer diagnosis and monitoring. Further research is needed to fully understand the potential clinical applications of USP41 and to develop safe and effective treatments.

Conclusion

In conclusion, USP41 (Ubiquitin specific peptidase 41) is a protein that plays a crucial role in the regulation of protein degradation and has been identified as a potential drug target and biomarker for the treatment of cancer. Its unique mechanism of action and its expression in various tissues and cells make it an attractive target for the development of new treatments for cancer. Further research is needed to fully understand the potential clinical applications of USP41 and to develop safe and effective treatments.

Protein Name: Ubiquitin Specific Peptidase 41

Functions: May recognize and hydrolyze the peptide bond at the C-terminal Gly of ubiquitin. Involved in the processing of poly-ubiquitin precursors as well as that of ubiquitinated proteins (By similarity)

The "USP41 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about USP41 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

USP42 | USP43 | USP44 | USP45 | USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7 | USP8 | USP8P1 | USP9X | USP9Y | USPL1 | UST | UTF1 | UTP11 | UTP14A | UTP14C | UTP15 | UTP18 | UTP20 | UTP23 | UTP25 | UTP3 | UTP4 | UTP6 | UTRN | UTS2 | UTS2B | UTS2R | UTY | UVRAG | UVSSA | UXS1 | UXT | UXT-AS1 | VAC14 | Vacuolar H+ ATPase | VAMP1 | VAMP2 | VAMP3 | VAMP4 | VAMP5 | VAMP7 | VAMP8 | VANGL1 | VANGL2 | VAPA | VAPB | VARS1 | VARS2 | Vascular endothelial growth factor receptor (VEGFR) | Vascular endothelial growth factors (VEGF) | VASH1 | VASH1-AS1 | VASH2 | VASN | Vasoactive intestinal polypeptide receptor (VIP-R) | Vasohibin | Vasopressin Receptor | Vasopressin V1 Receptor | VASP | VAT1 | VAT1L | VAV1 | VAV2 | VAV3 | VAV3-AS1 | VAX1 | VAX2 | VBP1 | VCAM1 | VCAN | VCL | VCP | VCPIP1 | VCPKMT | VCX | VCX2 | VCX3A | VCX3B | VCY | VCY1B | VDAC1 | VDAC1P2 | VDAC1P9 | VDAC2 | VDAC2P5 | VDAC3 | VDR